Your browser doesn't support javascript.
loading
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G; Davids, Matthew S; Choi, Michael; Cheson, Bruce D; Furman, Richard R; Lamanna, Nicole; Barr, Paul M; Zhou, Lang; Chyla, Brenda; Salem, Ahmed Hamed; Verdugo, Maria; Humerickhouse, Rod A; Potluri, Jalaja; Coutre, Steven; Woyach, Jennifer; Byrd, John C.
Affiliation
  • Jones JA; The Ohio State University, Columbus, OH, USA.
  • Mato AR; Center for Chronic Lymphocytic Leukemia, University of Pennsylvania, Philadelphia, PA, USA.
  • Wierda WG; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davids MS; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Choi M; UC San Diego Moores Cancer Center, San Diego, CA, USA.
  • Cheson BD; Georgetown University Hospital, Washington, DC, USA.
  • Furman RR; Weill Cornell Medicine, New York, NY, USA.
  • Lamanna N; Columbia University Medical Center, New York, NY, USA.
  • Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
  • Zhou L; AbbVie, North Chicago, IL, USA.
  • Chyla B; AbbVie, North Chicago, IL, USA.
  • Salem AH; AbbVie, North Chicago, IL, USA; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
  • Verdugo M; AbbVie, North Chicago, IL, USA.
  • Humerickhouse RA; AbbVie, North Chicago, IL, USA.
  • Potluri J; AbbVie, North Chicago, IL, USA.
  • Coutre S; Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA.
  • Woyach J; The Ohio State University, Columbus, OH, USA.
  • Byrd JC; Division of Pharmaceutics, College of Pharmacy, Columbus, OH, USA. Electronic address: john.byrd@osumc.edu.
Lancet Oncol ; 19(1): 65-75, 2018 01.
Article in En | MEDLINE | ID: mdl-29246803
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Sulfonamides / Leukemia, Lymphocytic, Chronic, B-Cell / Bridged Bicyclo Compounds, Heterocyclic / Protein Kinase Inhibitors / Antineoplastic Agents Type of study: Clinical_trials / Guideline Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Sulfonamides / Leukemia, Lymphocytic, Chronic, B-Cell / Bridged Bicyclo Compounds, Heterocyclic / Protein Kinase Inhibitors / Antineoplastic Agents Type of study: Clinical_trials / Guideline Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article Affiliation country: United States